Dechra Pharmaceuticals records rise in revenues and profits

Dechra Pharmaceuticals raised its dividend by 15.1 per cent as the company achieved higher revenues and profits during the second half of 2012.

Dechra Pharmaceuticals raised its dividend by 15.1 per cent as the company achieved higher revenues and profits during the second half of 2012.

The veterinary medicines company returned an interim dividend per share of 4.34p, compared to 3.77p for the same period a year earlier.

Group revenues climbed 20.4% year-on-year to £252.2m for the half year while profits before tax soared 29.25 to £11.5m.

Results were driven by strong performance of licensed branded veterinary products in specialist pet diets in key segments in Europe and the US.

Contract manufacturing saw double digit sales growth while the group's services segment realised solid revenues and a modest improvement in operating margin.

Dechra began to see rewards from the successful integration of Eurovet Animal Health which the company acquired last May. Eurovet is a Netherlands-based business which operates in the companion animal pharmaceuticals and farm animal pharmaceuticals markets.

"The first phase of the integration has progressed in line with our strategy and is delivering the expected cost and revenue synergies," the company said.

Net borrowings were up £102m at the end of the year, compared to £87m at June 30th and £46.1m at the end of 2011.

Operating profits jumped 37.3% to £15.1m while basic earnings per share increased 6.9% to 9.91p.

The firm's outlook for the year ahead was positive as trading was expected to remain robust. However, the company said it was cautious given the economic environment, particularly in European markets.

Dechra said bad weather also hit sales in the service sector in January but anticipates the segment will bounce back.

"The group continues to deliver its strategic objectives; with additional synergies from the Eurovet acquisition, new product introductions, improved efficiency and international expansion we remain well positioned to maintain our strong growth."

RD

Recommended

Improve your odds of investment success with these three stocks
Share tips

Improve your odds of investment success with these three stocks

Professional investor Tom Wildgoose of the Nomura Global High Conviction Fund highlights three of his favourite stocks.
2 Aug 2021
How to profit from pampered pets beyond the pandemic
Share tips

How to profit from pampered pets beyond the pandemic

Covid-19 has greatly boosted ownership. But the market had been expanding for years, and demographic, cultural and medical trends all point to long-te…
30 Jul 2021
Share tips of the week – 30 July
Share tips

Share tips of the week – 30 July

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
30 Jul 2021
Robinhood is going public – should you invest?
US stockmarkets

Robinhood is going public – should you invest?

Online stockbroking app Robinhood is going public on the US stock exchange. Saloni Sardana looks at whether it's worth a punt.
29 Jul 2021

Most Popular

Why the UK's 2.5% inflation is a big deal
Inflation

Why the UK's 2.5% inflation is a big deal

After years of inflation being a financial-assets problem, it is now an “ordinary things” problem too, says Merryn Somerset Webb. But central banks st…
16 Jul 2021
The MoneyWeek Podcast: Asia, financial repression and the nature of capitalism
Economy

The MoneyWeek Podcast: Asia, financial repression and the nature of capitalism

Russell Napier talks to Merryn about financial repression – or "stealing money from old people slowly" – plus how Asian capitalism is taking over in t…
16 Jul 2021
Cryptocurrency roundup: Twitter founder’s “DeFi” platform
Bitcoin & crypto

Cryptocurrency roundup: Twitter founder’s “DeFi” platform

In crypto this week: regulators are getting worried; Jack Dorsey’s bitcoin DeFi platform; and dogecoin’s co-founder lambasts cryptocurrencies.  Salon…
16 Jul 2021